Generics - Allergan


Current filters:


Popular Filters

Two more drug patents revoked in India


In another blow for intellectual property in India, local drugmaker Ajanta Pharma has prevailed in revoking…

Ajanta PharmaAllerganAsia-PacificCombiganGanfortGenericsOphthalmicsPatentsPharmaceutical

Migraine drug sales to grow to $5.8 billion in 2021 in major markets


Despite a decline in sales owing to the generic entry of most triptans, the launch of emerging acute…

AllerganBotoxCoLucidGenericsGloballasmiditanLevadexMAP PharmaceuticalsMarkets & MarketingPharmaceuticalResearch

Watson gets FDA approval for generic Sanctura XR and Avapro


US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has received approval from the US Food and Drug…

AllerganAvaproCardio-vascularGenericsGenito-urinaryNorth AmericaRegulationSanctura XRSanofiWatson Pharmaceuticals

Watson confirms Lumigan and Latisse patent challenges; favorable Sanctura ruling


US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

AllerganGenericsGenito-urinaryLatisseLegalLumiganOphthalmicsPatentsSanctura XRWatson Pharmaceuticals

Back to top